The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets
Open accessAbstract
Huntington's disease is a fatal neurodegenerative disorder caused by an expanded polyglutamine repeat in huntingtin (HTT) protein. We previously showed that calorie restriction ameliorated Huntington's disease pathogenesis and slowed disease progression in mice that model Huntington's disease (Huntington's disease mice). We now report that overexpression of sirtuin 1 (Sirt1), a mediator of the beneficial metabolic effects of calorie restriction, protects neurons against mutant HTT toxicity, whereas reduction of Sirt1 exacerbates mutant HTT toxicity. Overexpression of Sirt1 improves motor function, reduces brain atrophy and attenuates mutant-HTT–mediated metabolic abnormalities in Huntington's disease mice. Further mechanistic studies suggested that Sirt1 prevents the mutant-HTT–induced decline in brain-derived neurotrophic factor (BDNF) concentrations and the signaling of its receptor, TrkB, and restores dopamine- and cAMP-regulated phosphoprotein, 32 kDa (DARPP32) concentrations in the striatum. Sirt1 deacetylase activity is required for Sirt1-mediated neuroprotection in Huntington's disease cell models. Notably, we show that mutant HTT interacts with Sirt1 and inhibits Sirt1 deacetylase activity, which results in hyperacetylation of Sirt1 substrates such as forkhead box O3A (Foxo3a), thereby inhibiting its pro-survival function. Overexpression of Sirt1 counteracts the mutant-HTT–induced deacetylase deficit, enhances the deacetylation of Foxo3a and facilitates cell survival. These findings show a neuroprotective role for Sirt1 in mammalian Huntington's disease models and open new avenues for the development of neuroprotective strategies in Huntington's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: SIRT1 Suppresses β-Amyloid Production by Activating the α-Secretase Gene ADAM10
Donmez, G., Wang, D., Cohen, D. E., & Guarente, L. (2010) · Cell · doi:10.1016/j.cell.2010.06.020 · Cited by 432
RetractedStress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 1×
“Small compounds with Sirt1 activation activity have been shown to be beneficial in experimental animals prone to metabolic diseases 41 , and development of Sirt1 activators with high specificity and bioavailability may also be a promising approach for the treatment of Huntington’s disease.”
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Self-citationBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
DNA Repair Pathway Stimulated by the Forkhead Transcription Factor FOXO3a Through the Gadd45 Protein
Tran, H., Brunet, A., Grenier, J. M., Datta, S. R., Fornace, A. J., DiStefano, P. S., Chiang, L. W., & Greenberg, M. E. (2002) · Science · doi:10.1126/science.1068712 · Cited by 860
Rios, M., Fan, G., Fekete, C., Kelly, J., Bates, B., Kuehn, R., Lechan, R. M., & Jaenisch, R. (2001) · Molecular Endocrinology · doi:10.1210/me.15.10.1748 · Cited by 780
Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 753
Greengard, P., Allen, P. B., & Nairn, A. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)80798-9 · Cited by 746
SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.-F., Kwon, H., Yi, S., Mucke, L., & Gan, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509329200 · Cited by 740
Normal huntingtin function: an alternative approach to Huntington's disease
Cattaneo, E., Zuccato, C., & Tartari, M. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1806 · Cited by 657
Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X.-H., Tao, J., Yamazaki, I., Li, S.-H., Sun, Y. E., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0857-08.2008 · Cited by 613
Self-citationWeydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562
Self-citationRole of brain-derived neurotrophic factor in Huntington's disease
ZUCCATO, C., & CATTANEO, E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.003 · Cited by 552
Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons
Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., & Néri, C. (2005) · Nature Genetics · doi:10.1038/ng1534 · Cited by 512
DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission
Fienberg, A. A., Hiroi, N., Mermelstein, P. G., Song, W.-J., Snyder, G. L., Nishi, A., Cheramy, A., O'Callaghan, J. P., Miller, D. B., Cole, D. G., et al. (1998) · Science · doi:10.1126/science.281.5378.838 · Cited by 491
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 2×
“We previously showed that calorie restriction ameliorated Huntington’s disease pathogenesis and slowed disease progression in mice that model Huntington’s disease (Huntington’s disease mice) 1 .”
Self-citationde la Monte, S. M., Vonsattel, J.-P., & Richardson, E. P. (1988) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198809000-00003 · Cited by 428
Jeong, H., Cohen, D. E., Cui, L., Supinski, A., Savas, J. N., Mazzulli, J. R., Yates, J. R., Bordone, L., Guarente, L., & Krainc, D. (2012) · Nature Medicine · doi:10.1038/nm.2559 · Cited by 367
Self-citationSystematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models
Menalled, L., El-Khodor, B. F., Patry, M., Suárez-Fariñas, M., Orenstein, S. J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X. W., MacDonald, M., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.007 · Cited by 324
Self-citationNakagawa, T., Tsuchida, A., Itakura, Y., Nonomura, T., Ono, M., Hirota, F., Inoue, T., Nakayama, C., Taiji, M., & Noguchi, H. (2000) · Diabetes · doi:10.2337/diabetes.49.3.436 · Cited by 323
SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress
Kobayashi, Y., Furukawa-Hibi, Y., Chen, C., Horio, Y., Isobe, K., Ikeda, K., & Motoyama, N. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.16.2.237 · Cited by 313
Oxidative Damage in Huntington's Disease Pathogenesis
Browne, S. E., & Beal, M. F. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.2061 · Cited by 310
Brain SIRT1: Anatomical Distribution and Regulation by Energy Availability
Ramadori, G., Lee, C. E., Bookout, A. L., Lee, S., Williams, K. W., Anderson, J., Elmquist, J. K., & Coppari, R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-08.2008 · Cited by 310
The insulin paradox: aging, proteotoxicity and neurodegeneration
Cohen, E., & Dillin, A. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2474 · Cited by 303
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice
Bibb, J. A., Yan, Z., Svenningsson, P., Snyder, G. L., Pieribone, V. A., Horiuchi, A., Nairn, A. C., Messer, A., & Greengard, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120166397 · Cited by 289
Gines, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg046 · Cited by 276
Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., & Marsh, J. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn273 · Cited by 265
Satoh, A., Brace, C. S., Ben-Josef, G., West, T., Wozniak, D. F., Holtzman, D. M., Herzog, E. D., & Imai, S.-I. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1385-10.2010 · Cited by 237
Self-citationStrand, A. D., Baquet, Z. C., Aragaki, A. K., Holmans, P., Yang, L., Cleren, C., Beal, M. F., Jones, L., Kooperberg, C., Olson, J. M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2461-07.2007 · Cited by 212
CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model
Chou, S., Lee, Y., Chen, H., Chiang, M., Lai, H., Chang, H., Wu, Y., Sun, C., Chien, C., Lin, Y., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03029.x · Cited by 173
Bohanna, I., Georgiou-Karistianis, N., Hannan, A. J., & Egan, G. F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.04.001 · Cited by 168
Oliveira, J. M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06741.x · Cited by 163
Duan, W., Peng, Q., Masuda, N., Ford, E., Tryggestad, E. J., Ladenheim, B., Zhao, M., Cadet, J. L., Wong, J., & Ross, C. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.015 · Cited by 143
Self-citationChaturvedi, R. K., Calingasan, N. Y., Yang, L., Hennessey, T., Johri, A., & Beal, M. F. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq229 · Cited by 142
Brain‐derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice
Nakagawa, T., Ono‐Kishino, M., Sugaru, E., Yamanaka, M., Taiji, M., & Noguchi, H. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.290 · Cited by 133
PGC-1α, a New Therapeutic Target in Huntington's Disease?
McGill, J. K., & Beal, M. F. (2006) · Cell · doi:10.1016/j.cell.2006.10.023 · Cited by 131
Albani, D., Polito, L., & Forloni, G. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1215 · Cited by 124
Modulation of SIRT1 expression in different neurodegenerative models and human pathologies
Pallàs, M., Pizarro, J. G., Cuesta, J., Crespo‐Biel, N., Alvira, D., Tajes, M., Yeste‐Velasco, M., Folch, J., Canudas, A. M., Sureda, F. X., et al. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.065 · Cited by 116
Chopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W. R., Waldmeier, P. C., Housman, D. E., Kazantsev, A. G., Young, A. B., & Hersch, S. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707842104 · Cited by 113
Therapeutic Potential of Fluoxetine in Neurological Disorders
Mostert, J. P., Koch, M. W., Heerings, M. A. P., Heersema, D. J., & Keyser, J. D. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1527-3458.2008.00040.x · Cited by 103
A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer
Morris, B. J. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000173509.45363.dd · Cited by 99
Mojsilovic‐Petrovic, J., Nedelsky, N. B., Boccitto, M., Mano, I., Georgiades, S. N., Zhou, W., Liu, Y., Neve, R. L., Taylor, J. P., Driscoll, M., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1805-09.2009 · Cited by 97
Zhang, J., Peng, Q., Li, Q., Jahanshad, N., Hou, Z., Jiang, M., Masuda, N., Langbehn, D. R., Miller, M. I., Mori, S., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.027 · Cited by 94
Self-citationParoxetine retards disease onset and progression in Huntingtin mutant mice
Duan, W., Guo, Z., Jiang, H., Ladenheim, B., Xu, X. Z. S., Cadet, J. L., & Mattson, M. P. (2004) · Annals of Neurology · doi:10.1002/ana.20075 · Cited by 90
Self-citationIvković, S., Polonskaia, O., Fariñas, I., & Ehrlich, M. E. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00684-7 · Cited by 79
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice
Simmons, D. A., Mehta, R. A., Lauterborn, J. C., Gall, C. M., & LYNCH, G. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.015 · Cited by 78
Bithell, A., Johnson, R., & Buckley, N. J. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371270 · Cited by 71
Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice
Li, M., Huang, Y., Ma, A. A. K., Lin, E., & Diamond, M. I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.011 · Cited by 68
Extraction of intracellular nucleosides and nucleotides with acetonitrile.
Au, J. L. ‐., Su, M., & Wientjes, M. G. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.1.48 · Cited by 64
Huntington’s Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy
Sari, Y. (2011) · International Journal of Biomedical Science · doi:10.59566/ijbs.2011.7089 · Cited by 63
Mitochondrial matters of the brain: the role in Huntington’s disease
Turner, C., & Schapira, A. H. V. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9290-y · Cited by 45
Sirtuins: Common Targets in Aging and in Neurodegeneration
de Oliveira, R. M., Pais, T. F., & Outeiro, T. F. (2010) · Current Drug Targets · doi:10.2174/1389450111007011270 · Cited by 45
Wang, W., Duan, W., Igarashi, S., Morita, H., Nakamura, M., & Ross, C. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.026 · Cited by 41
Self-citationKnockdown of FoxO3a induces increased neuronal apoptosis during embryonic development in zebrafish
Peng, K., Li, Y., Long, L., Li, D., Jia, Q., Wang, Y., Shen, Q., Tang, Y., Wen, L., Kung, H., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.07.068 · Cited by 31
Transcription meets metabolism in neurodegeneration
Ross, C. A., & Thompson, L. M. (2006) · Nature Medicine · doi:10.1038/nm1106-1239 · Cited by 31
Self-citationHuntington’s Disease – New Perspectives Based on Neuroendocrine Changes in Rodent Models
Petersén, Å., Hult, S., & Kirik, D. (2009) · Neurodegenerative Diseases · doi:10.1159/000225377 · Cited by 27
Potential Drugs and Methods for Preventing or Delaying the Progression of Huntington's Disease
Sari, Y. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488911795933884 · Cited by 13
Gan, B. Q., & Tang, B. L. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00597.x · Cited by 11
Cited by
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Mitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Self-citationSIRT1 Mediates Central Circadian Control in the SCN by a Mechanism that Decays with Aging
Chang, H.-C., & Guarente, L. (2013) · Cell · doi:10.1016/j.cell.2013.05.027 · Cited by 615
Radak, Z., Zhao, Z., Koltai, E., Ohno, H., & Atalay, M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4498 · Cited by 605
Metadata
- Authors
- Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H., Seredenina, T., Arbez, N., Zhu, S., Sommers, K., Qian, J., Zhang, J., Mori, S., Yang, X. W., Tamashiro, K. L. K., Aja, S., Moran, T. H., Luthi-Carter, R., Martin, B., Maudsley, S., Mattson, M. P., Cichewicz, R. H., Ross, C. A., Holtzman, D. M., Krainc, D., & Duan, W.
- Venue
- Nature Medicine
- Published
- 2011-12-18
- Volume
- 18
- Issue
- 1
- Pages
- 153-158
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1978511426
- Cited by
- 345
- References
- 66
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.